Acute infusion reactions induced by monoclonal antibody therapy.
about
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondAlemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for useInfliximab-Related Infusion Reactions: Systematic ReviewInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Perioperative effects of high doses of intraoperative thymoglobulin induction in liver transplantation.Monoclonal antibodies: longitudinal prescribing information analysis of hypersensitivity reactions.Development and treatments of inflammatory cells and cytokines in spinal cord ischemia-reperfusion injury.Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactionsLong-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.The use of immune modulating drugs for the treatment of multiple sclerosis.Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.Prevention of anaphylaxis in healthcare settings.Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature.Monoclonal antibodies as therapeutics in human malignancies.Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.The safety of monoclonal antibodies in asthma.Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France.Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils.
P2860
Q26800128-C320E76D-ABFB-4A22-84BA-72E1EE761A33Q26849781-5B2C131E-0112-4A61-BB34-30AE20C4DD40Q27013835-94013101-17C3-40B7-A81F-3DDF718D13E1Q30240229-122D919C-4FD5-4156-B226-299600D1644BQ33428849-74AD2C1D-49F3-47BB-8DF1-88945D3A5792Q35969876-98946FE9-07D5-4D20-B1F7-EC201FE803F1Q37057821-79811096-8414-407A-92A6-68A7DDB048ADQ37412095-442329B2-8635-4300-894A-FEFF0F9887C7Q37453033-3D2477E1-AD35-4AA7-AD0A-4960ADBB13B1Q37577290-395783A5-9BD0-4279-A5C7-AF1605CC571DQ37965600-17CEC5A3-98DC-431C-AAE0-A50BB8BE2BE5Q38087506-E8B771AD-60F6-4174-92E8-8EDB402B3859Q38132699-97B9A365-605A-4C52-8D19-E464C41543FAQ38144110-0DA1072B-6388-43BE-AEB3-57EEA3AB6CEEQ38174643-15F482F8-B584-48B4-AE78-585D89D4F8EAQ38206275-68AEB755-D31C-47DA-930E-9F33C1B76ADFQ38650602-FBCB29AA-56D5-4DF3-AD96-8BCF92FD97E1Q38842153-150D2BC0-00FC-4F8B-AB14-99D051D94138Q39744600-D1CFB4E7-18CF-459F-8646-506498C943A3Q42987371-AC424EEA-2276-45B0-B30D-71B6B5AE0574Q43876841-C9700952-5259-4DB3-9FE9-300F5D6F34E6Q44477550-54ED40BC-A1B9-4059-BF75-1CCB898DAF50Q44757011-1159BE1B-EAB8-4B35-BFA1-CD0C61D97BEEQ47942947-EE7E5355-050D-4BD7-9717-0BC06A830EE7Q48196935-AFA94B0D-CD25-45C5-8AA9-DB4F504301C6Q50205188-342A58D2-1E94-4FBC-B1FE-EAA53CE227D7Q51036254-C90BDA1E-5262-42A7-AF28-E0B352AF0995Q55454180-227E9835-1CDC-4A12-B405-9EA97092135B
P2860
Acute infusion reactions induced by monoclonal antibody therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute infusion reactions induced by monoclonal antibody therapy.
@en
Acute infusion reactions induced by monoclonal antibody therapy.
@nl
type
label
Acute infusion reactions induced by monoclonal antibody therapy.
@en
Acute infusion reactions induced by monoclonal antibody therapy.
@nl
prefLabel
Acute infusion reactions induced by monoclonal antibody therapy.
@en
Acute infusion reactions induced by monoclonal antibody therapy.
@nl
P2093
P2860
P356
P1476
Acute infusion reactions induced by monoclonal antibody therapy.
@en
P2093
Alessandra Vultaggio
Andrea Matucci
Enrico Maggi
P2860
P356
10.1586/ECI.10.90
P577
2011-01-01T00:00:00Z